Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
For ongoing discussions, tips, and to connect with our team, be sure to follow us on our Facebook page
However, PRP has substantially more clinical evidence supporting its use and established safety profiles for numerous applications
SLU-PP-332 may take 60120 seconds
This service is billed using CPT code 77300
El GHK-Cu es uno de los pocos pptidos bioactivos que ha sido objeto de estudios clnicos en el mbito dermatolgico
US$ 29.18
US$ 22.39
US$ 21.75
US$ 26.80
US$ 21.07
US$ 24.70
US$ 24.72
